Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

June 2015

Prior Authorization Required for Corlanor 

Effective immediately, Harvard Pilgrim is covering the medication Corlanor with prior authorization. In April, the U.S. Food and Drug Administration (FDA) approved Corlanor (ivabradine) — which is a hyperpolarization-activated cyclic nucleotide-gated channel blocker — for use in reducing the risk of hospitalization for worsening heart failure in select patients.

Corlanor will be covered on the Premium formularies only, at the highest tier (i.e. Tier 3 on the 3-Tier and Tier 4 on the 4-Tier). Harvard Pilgrim is requiring prior authorization to ensure the safe and appropriate use of Corlanor. Harvard Pilgrim's Corlanor Clinical Coverage Criteria detail the requirements that must be met in order to obtain prior authorization, including:

  • Patient has a diagnosis of symptomatic chronic heart failure (NYHA class II-IV) with left ventricular ejection fraction (EF) < 35%
  • Corlanor is prescribed by a cardiologist or specialist in cardiac care
  • Patient has a resting heart beat > 70 beats or more per minute
  • Patient is on maximally tolerated doses of beta blockers (e.g., carvedilol, metoprolol succinate, bisoprolol) or has a contraindication to beta blockers

Approvals will be valid for 12 months. To request prior authorization, please complete the Corlanor Medication Request Form and fax it to MedImpact Healthcare Systems at 888-807-6643. For more information, please refer to the Pharmacy section of Harvard Pilgrim's provider website.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Reimbursement for Certain Vaccines in Massachusetts

Harvard Pilgrim 271 Eligibility Response Enhancements

Update on CAQH Transition


Reminder: Prior Authorization of Select Surgical Procedures

Prior Authorization Required for Corlanor

A Valuable Resource for Safe Opioid Prescribing

Recognizing and Identifying Symptoms of Eating Disorders


Reminder: Keep Panel Status Up to Date


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator